Estimates Revisions Intellia Therapeutics, Inc.
Equities
NTLA
US45826J1051
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.78 USD | +3.65% |
|
+11.13% | +64.40% |
| Mar. 06 | Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) | RE |
| Mar. 03 | Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- NTLA Stock
- Consensus Intellia Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
